title: Ruxolitinib for myelofibrosis: from 'palliation' to prolongation of survival.
authors: Department ofLeukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
authors: Srdan
authors: S
authors: Verstovsek
mesh_terms: D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans; D009570:Nitriles; D055728:Primary Myelofibrosis / Q000188:drug therapy*; D011720:Pyrazoles / Q000627:therapeutic use*; D011743:Pyrimidines
chemical_list: D004791:Enzyme Inhibitors; D009570:Nitriles; D011720:Pyrazoles; D011743:Pyrimidines; C540383:ruxolitinib
references: Blood. 2012 Sep 27;120(13):2768-9
references: 23019204
references: Curr Med Chem. 2012;19(26):4399-413
references: 22830345
references: Postgrad Med. 2013 Jan;125(1):128-35
references: 23391678
references: Leuk Lymphoma. 2014 Jan;55(1):195-7
references: 23647081
references: J Clin Oncol. 2013 Apr 1;31(10):1285-92
references: 23423753
references: Oncology (Williston Park). 2013 Jul;27(7):706-14
references: 23977767
references: Blood. 2013 Jun 13;121(24):4832-7
references: 23570800